DOCSLIB.ORG

(19) United States (12) Patent Application Publication (10) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(19) United States (12) Patent Application Publication (10) Pub US 20100034767A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0034767 A1 Trabelsi (43) Pub. Date: Feb. 11, 2010 (54) COMPOSITION FOR MAKING UP THE LIPS (30) Foreign Application Priority Data (75) Inventor: Vanessa Trabelsi, Villemomble Jan. 23, 2007 (FR) .................................... .. 07/00457 (FR) Publication Classi?cation Correspondence Address: YOUNG 8‘ THOMPSON (51) .I4n6tiI€l§1/74 (2006 01) 209 Madison Street, Suite 500 A61Q 90/00 (2009'01) Alexandria, VA 22314 (US) ' (52) US. Cl. ................................................... .. 424/78.03 (73) Assignee: CHANEL PARFUMS BEAUTE, Neuilly Sur Seine (FR) (57) ABSTRACT 21 A l. N .: 12/524 108 A cosmetic com p osition in the form of a Water-in-oil emul ( ) pp 0 ’ sion includes a fatty phase and an aqueous phase, the fatty (22) PCT Filed: Jam 23, 2008 phase of Which includes at least one hydrocarbon oil, at least one ?rst copolymer of ethylene and of propylene and at least (86) PCT NO; PCT/EP08/50780 one second copolymer of styrene and of at least one ole?n other than styrene. A cosmetic method for caring for or mak § 371 (0X1), ing up skin or the lips, and the topical application to the lips of (2), (4) Date: Jul. 22, 2009 this composition are also disclosed. US 2010/0034767 A1 Feb. 11, 2010 COMPOSITION FOR MAKING UP THE LIPS copolymer of ethylene and of propylene, and at least one second copolymer of styrene and of at least one ole?n other than styrene. [0014] For greater transparency, the refractive index of the [0001] The present invention relates to a cosmetic compo sition in the form of a Water-in-oil emulsion comprising at aqueous phase can advantageously be increased by providing for the aqueous phase to include at least one polyol. Polyg least one non volatile hydrocarbon oil, at least one ?rst copolymer of ethylene and of propylene, and at least one lycerol-6 is preferred in so far as it brings about a big increase second copolymer of styrene and of at least one ole?n other in the refractive index of the aqueous phase. than styrene. Non Volatile Hydrocarbon Oil [0002] It also relates to a cosmetic method for caring or making up the face comprising the topical application of this [0015] As indicated above, the composition includes at composition on the keratinous material. least one non volatile hydrocarbon oil. [0003] The present invention deals With compositions for [0016] Within the meaning of the present invention, the making up the skin, nails, eyelashes, eyebroWs, or the lips, term “oil” is understood to mean a compound Which is liquid such as foundations, eyeshadoWs, lipsticks, lip gloss prod at ambient temperature (25° C.) and Which, When it is intro ucts, products for concealing rings under the eyes, blushers, duced in a proportion of at least 1% by Weight into Water at mascaras, eyeliners, lip pencils, eyeliner pencils, nail var 25° C., is not at all soluble in Water or soluble to a level ofless nishes. than 10% by Weight, With respect to the Weight of oil intro duced into the Water. [0004] According preferred embodiments, the cosmetic [0017] The term “hydrocarbon oil” is understood to mean composition is a lip gloss product, a foundation base or a product for the styling of eyebroWs. an oil comprising hydrogen and carbon atoms, and containing no silicon atoms. [0005] One aim of the present invention is to provide a [0018] Within the meaning of the present invention, the cosmetic composition giving a fresh feeling upon application, term “non volatile oil” is understood to mean an oil Which has having a good Wear during the day, and having a good level of a vapour pressure at ambient temperature and atmospheric transparency. pressure, loWer that 0.13 Pa (10'3 mm Hg). [0006] The product is preferably non opaque, it means it is [0019] Hydrocarbon oils having a loW or moderate polarity transparent or translucent. are preferred, such as ester oils bearing no polar groups and [0007] A Way to obtain cosmetic products having a good hydrocarbure oils. Wear on keratinous materials is usually to include signi?cant [0020] When intended for lip application, the hydrocarbon proportions of volatile oils. Nevertheless, such large amount oil preferably have a high refractive index, typically above of volatile oils decrease comfort and gloss of said composi 1.45, or even above 1.47. tions. [0021] The non volatile hydrocarbon oil present in the com [0008] One aim of the present invention is to provide a position according to the invention may be chosen from cosmetic composition giving a fresh fccling upon application, hydrocarbures, i.e. oils made of carbon and hydrogen atoms. having a good Wear during the day, and having a minimum It can in particular be chosen from polybutene, hydrogenated gloss effect. According one embodiment, the composition polyisobutene and hydrogenated polydecene. It is preferably according to the invention contains loW amounts of volatile hydrogenated polydecene. oils and still performs good Wear on lips or skin. [0022] According to the invention, the non volatile hydro [0009] In this context, the aim of the present invention is to carbon oils can also be chosen chosen from esters of mono provide a composition for making up the skin, the eyebroWs carboxylic acids preferably monoesters. or the lips, Which is translucent or transparent, and provides a [0023] Advantageously, said esters correspond to the fol freshening feeling to the consumer When applied on the kera loWing formula (I): tinous material. [0010] In order to solve this problem, the Applicant has Where R1 represents a linear or branched alkyl radical of 1 to looked for a Water-in-oil emulsion containing non volatile 40 carbon atoms, preferably of 7 to 19 carbon atoms, option hydrocarbon. He has surprisingly found that the mixture of ally comprising one or more ethylenic double bonds, and tWo speci?c copolymers makes it possible to loWer the refrac optionally substituted, tive index of a fatty phase comprising a non volatile hydro [0024] R2 represents a linear or branched alkyl radical of 1 carbon oil to bring it closer to that of an aqueous phase. to 40 carbon atoms, preferably of 3 to 30 carbon atoms and [0011] The aim of the present invention is achieved by the even better of 3 to 20 carbon atoms, optionally comprising use, in an emulsion of Water-in-oil type comprising a non one or more ethylenic double bonds. volatile hydrocarbon oil, of a combination of at least tWo [0025] R2 can also represent an aryl radical, for example speci?c copolymers. benZyl. [0012] A subject-matter of the present invention is thus a [0026] The number of carbon of said ester preferably goes cosmetic composition in the form of a Water-in-oil emulsion from 10 to 40, and is typically around 20. comprising at least one non volatile hydrocarbon oil, at least [0027] R1 may represent the residue of a preferably higher, one ?rst copolymer of ethylene and of propylene and at least linear or, preferably branched fatty acid comprising from 1 to one second copolymer of styrene and of at least one ole?n 40 and even better from 7 to 19 carbon atoms and R2 may other than styrene. represent a linear or preferably branched hydrocarbon chain [0013] The Water-in-oil emulsion includes a fatty phase and containing from 1 to 40, preferably from 3 to 30 and even an aqueous phase, and the fatty phase preferably comprises at better from 3 to 20 carbon atoms. Examples of R1 groups are least one non volatile hydrocarbon oil, at least one ?rst those derived from fatty acids chosen from the group consist US 2010/0034767 A1 Feb.11, 2010 ing of acetic, propionic, butyric, caproic, caprylic, pelargonic, dients of the composition. Said non volatile hydrocarbon oil capric, undecanoic, lauric, myristic, palmitic, stearic, isos can be one of the oils described hereabove. tearic, arachidic, behenic, oleic, linolenic, linoleic, oleo [0050] As an example, second copolymer can be a blend of stearic, arachidonic and erucic acids, and mixtures thereof. ethylene/propylene/ styrene copolymer and butylene/ethyl [0028] Examples of esters Which can be used in the fatty ene/ styrene copolymer. phases of the compositions of the invention are for example [0051] The ?rst and second copolymers are preferably purcellin oil (cetostearyl octanoate), isononyl isononanoate, included in the fatty phase of the Water-in-oil emulsion isopropyl myristate, isopropyl palmitate, 2-ethylhexyl palmi according to the invention. tate, C12-C15 ester benZoate, 2-octyldodecyl stearate, 2-oc [0052] The ratio of second to ?rst copolymer goes advan tyldodecyl erucate, isostearyl isostearate, and heptanoates, tageously from 1/ 10 to 20/ 1, more preferably from 1/ 2 to 5/ 1, octanoates, decanoates or ricinoleates of alcohols or polyal preferably from 1/1 to 2/ 1. cohols, for example of fatty alcohols. [0053] The amount of second copolymer goes advanta [0029] The ester oil Will be preferably chosen from the geously from 0.1 to 10% by Weight of the total Weight of the following compounds: composition, preferably from 0.5 to 5%. [0030] isononyl isononanoate, [0031] isopropyl palmitate, Other Ingredients [0032] isostearyl isostearate. [0054] Apart from the non volatile hydrocarbon oil, the [0033] The non volatile hydrocarbon oil amount advanta Water-in-oil emulsion according to the invention can include geously goes from 5 to 35% by Weight of the total Weight of at least one other oil chosen in particular from: the composition, preferably from 10 to 30% by Weight of the [0055] synthetic (poly)esters and (poly)ethers, vegetable total Weight of the composition. oils, branched and/or unsaturated fatty acids, such as octyl First Copolymer dodecanol, branched and/or unsaturated fatty alcohols, sili cone oils, such as linear polydimethylsiloxanes, Which are [0034] The ?rst copolymer can be an ethylene/propylene optionally phenylated, or cyclic polydimethylsiloxanes, ?uo copolymer in dispersion in a non volatile hydrocarbon oil.
Load more

Recommended publications
  • Inline-Supplementary-Material-1.Pdf
    Appendix 1: STOPP/START criteria version 2 applied to the TRUST dataset Physiological system Criteria Criteria included Number (%) (The relevant () criteria for each participant were applied to the dataset and recorded in of Microsoft Office Excel ® (2013)) criteria included out of total criteria STOPP criteria Indication of medication A1. Any drug prescribed without an evidence-based clinical indication. X 1/3 (33.3) A2. Any drug prescribed beyond the recommended duration, where treatment duration is X well defined. A3. Any duplicate drug class prescription e.g. two concurrent NSAIDs, SSRIs, loop diuretics, ACE inhibitors, anticoagulants (optimisation of monotherapy within a single drug class should be observed prior to considering a new agent). Cardiovascular system B1. Digoxin for heart failure with preserved systolic ventricular function (no clear evidence X 7/13 (53.8) of benefit). B2. Verapamil or diltiazem with NYHA Class III or IV heart failure (may worsen heart failure). B3. Beta-blocker in combination with verapamil or diltiazem (risk of heart block). B4. Beta blocker with symptomatic bradycardia (< 50/min), type II heart block or complete heart block (risk of profound hypotension, asystole). B5. Amiodarone as first-line antiarrhythmic therapy in supraventricular tachyarrhythmias X (higher risk of side-effects than beta-blockers, digoxin, verapamil or diltiazem). B6. Loop diuretic as first-line treatment for hypertension (safer, more effective alternatives available). B7. Loop diuretic for dependent ankle oedema without clinical, biochemical evidence or radiological evidence of heart failure, liver failure, nephrotic syndrome or renal failure (leg elevation and /or compression hosiery usually more appropriate). B8. Thiazide diuretic with current significant hypokalaemia (i.e.
    [Show full text]
  • Raynaud's Phenomenon and the Possible Use of Foods
    JFS R: Concise Reviews/Hypotheses in Food Science Raynaud’s Phenomenon and the Possible Use of Foods CHRIS I. WRIGHT, CHRISTINE I. KRONER, AND RICHARD DRAIJER R: Concise Reviews in Food Science ABSTRACT: In this article we focus on the possible use of foods to alleviate Raynaud’s phenomenon (RP). RP is evoked, predominately, by cold and results in a potent vascular constriction of the microvascular blood vessels in the hands, thus leading to reduced hand blood flow and the elevation of pain sensation. To alleviate RP by diet, food components need to be able to promote hand skin blood flow, which may be achieved using fish oil, garlic, ginkgo biloba, L-carnitine, or inositol nicotinate, or to increase hand skin temperature, using evening primrose oil, ginkgo biloba, or inositol nicotinate. Although there are a number of studies documenting such improvements with these ingredients, they often are poorly designed. Hence, there is a need for more controlled studies to substantiate their use, but also to test alternative foods or target new ones. Therefore, we also discuss some alternate food options and briefly outline clinical drugs for the treatment of RP, as their mechanisms of action may also be possible targets for food. It is the intention of this article to address the research needs of this field and to provide a better understanding of alternative options for those with RP. Keywords: Raynaud’s, vascular constriction, dietary intervention, nutraceutical, functional foods Introduction Mahoney 1999; Generini and others 2003; Herrick 2003); however, lit- here are a growing number of studies focusing on the con- tle work has been published on the use of foods as a complementary Tceivable health benefits of foods, botanicals, and supplements treatment for RP patients or as a safeguard for those at high or future (Boelsma and others 2001; Green and others 2003).
    [Show full text]
  • Poisons and Narcotic Drugs (Amendment) Ordinance 1988
    AUSTRALIAN CAPITAL TERRITORY Poisons and Narcotic Drugs (Amendment) Ordinance 1988 No. 96 of 1988 I, THE GOVERNOR-GENERAL of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Ordinance under the Seat of Government (Administration) Act 1910. Dated 15 December 1988 N. M. STEPHEN Governor-General By His Excellency’s Command, CLYDE HOLDING Minister of State for the Arts and Territories An Ordinance to amend the Poisons and Narcotic Drugs Ordinance 1978 Short title 1. This Ordinance may be cited as the Poisons and Narcotic Drugs (Amendment) Ordinance 1988.1 Commencement 2. This Ordinance commences on such date as is fixed by the Minister by notice in the Gazette. Principal Ordinance 3. In this Ordinance, “Principal Ordinance” means the Poisons and Narcotic Drugs Ordinance 1978.2 (Ord. 79/88)—Cat. No. Authorised by the ACT Parliamentary Counsel—also accessible at www.legislation.act.gov.au 2 Poisons and Narcotic Drugs (Amendment) No. 96, 1988 Substances to which Division applies 4. Section 27B of the Principal Ordinance is amended by adding at the end the following paragraphs: “; (f) follicle stimulating hormone; (g) luteinising hormone; (h) thalidomide.”. Grant of authorisation 5. Section 27E of the Principal Ordinance is amended— (a) by omitting from paragraph (1) (a) “or cyclofenil” and substituting “, cyclofenil, follicle stimulating hormone or luteinising hormone”; (b) by omitting from paragraph (1) (b) “and”; and (c) by adding at the end of subsection (1) the following word and paragraph: “; and (d) in the case of an application that relates to thalidomide— the applicant is a specialist physician with no less than 5 years’ experience in the treatment of erythema nodosum leprosum.”.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Raynaud's Phenomenon and Erythromelalgia
    Temperature-associated vascular disorders: Raynaud’s phenomenon and erythromelalgia. INTRODUCTION We are too much accustomed to attribute to a single cause that which is the product of several, and the majority of our controversies come from that. Baron Justus von Leibig (1803-73) Superficially, Raynaud's phenomenon, a disease associated with cold, and erythromelalgia, a warmth related disorder, could be considered the antithesis of each other. However, both these microcirculatory disorders, first described in the second half of the nineteenth century, have many features in common and, indeed, may share the same etiology, that is microvascular ischemia. The complicated structure that is the microcirculation can produce a variety of responses to a single noxious stimulus with sensations of cold and heat at opposite ends of the spectrum. In this chapter Raynaud's phenomenon and erythromelalgia -are compared and contrasted so that the correct diagnosis of 'these conditions and appropriate remedy can be selected by the clinician. Raynaud's Phenomenon Maurice Raynaud first defined the syndrome which bears his name 133 years ago.1 He described episodic digital ischemia provoked by cold and emotion. It is classically manifest by pallor of the affected part followed by cyanosis and rubor. Vasospasm in the digital vessels leads to the pallor (Fig. 22.1). The subsequent static venous blood leads to the development of cyanosis. The rubor is caused by hyperemia after the return of blood flow. Raynaud's phenomenon (RP) can be a benign condition but, if severe, can cause digital ulceration and gangrene. It is nine times more common in women than in men and has an overall prevalence in the population of approximately 10%, although it may affect as many as 20-30% of women in the younger age groups.2 There is also a familial predisposition which is more marked if the age of onset is less than 30 years.3 Until recently little was known about the true etiology and the extent of the disorder.
    [Show full text]
  • Medicines Regulations 1984 (SR 1984/143)
    Reprint as at 1 April 2020 Medicines Regulations 1984 (SR 1984/143) David Beattie, Governor-General Order in Council At the Government House at Wellington this 5th day of June 1984 Present: His Excellency the Governor-General in Council Pursuant to section 105 of the Medicines Act 1981, and, in the case of Part 3 of the regulations, to section 62 of that Act, His Excellency the Governor-General, acting on the advice of the Minister of Health tendered after consultation with the organisations and bodies that appeared to the Minister to be representatives of persons likely to be substantially affected, and by and with the advice and consent of the Executive Coun- cil, hereby makes the following regulations. Contents Page 1 Title and commencement 5 2 Interpretation 5 Part 1 Classification of medicines 3 Classification of medicines 9 Note Changes authorised by subpart 2 of Part 2 of the Legislation Act 2012 have been made in this official reprint. Note 4 at the end of this reprint provides a list of the amendments incorporated. These regulations are administered by the Ministry of Health. 1 Reprinted as at Medicines Regulations 1984 1 April 2020 Part 2 Standards 4 Standards for medicines, related products, medical devices, 10 cosmetics, and surgical dressings 4A Standard for CBD products 10 5 Pharmacist may dilute medicine in particular case 11 6 Colouring substances [Revoked] 11 Part 3 Advertisements 7 Advertisements not to claim official approval 11 8 Advertisements for medicines 11 9 Advertisements for related products 13 10 Advertisements
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services
    Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services Australian Statistics on Medicines 1997 i © Commonwealth of Australia 1998 ISBN 0 642 36772 8 This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be repoduced by any process without written permission from AusInfo. Requests and enquiries concerning reproduction and rights should be directed to the Manager, Legislative Services, AusInfo, GPO Box 1920, Canberra, ACT 2601. Publication approval number 2446 ii FOREWORD The Australian Statistics on Medicines (ASM) is an annual publication produced by the Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee. Comprehensive drug utilisation data are required for a number of purposes including pharmacosurveillance and the targeting and evaluation of quality use of medicines initiatives. It is also needed by regulatory and financing authorities and by the Pharmaceutical Industry. A major aim of the ASM has been to put comprehensive and valid statistics on the Australian use of medicines in the public domain to allow access by all interested parties. Publication of the Australian data facilitates international comparisons of drug utilisation profiles, and encourages international collaboration on drug utilisation research particularly in relation to enhancing the quality use of medicines and health outcomes. The data available in the ASM represent estimates of the aggregate community use (non public hospital) of prescription medicines in Australia. In 1997 the estimated number of prescriptions dispensed through community pharmacies was 179 million prescriptions, a level of increase over 1996 of only 0.4% which was less than the increase in population (1.2%).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,283,192 B2 Mullen Et Al
    US009283192B2 (12) United States Patent (10) Patent No.: US 9,283,192 B2 Mullen et al. (45) Date of Patent: Mar. 15, 2016 (54) DELAYED PROLONGED DRUG DELIVERY 2009. O1553.58 A1 6/2009 Diaz et al. 2009,02976O1 A1 12/2009 Vergnault et al. 2010.0040557 A1 2/2010 Keet al. (75) Inventors: Alexander Mullen, Glasgow (GB); 2013, OO17262 A1 1/2013 Mullen et al. Howard Stevens, Glasgow (GB); Sarah 2013/0022676 A1 1/2013 Mullen et al. Eccleston, Scotstoun (GB) FOREIGN PATENT DOCUMENTS (73) Assignee: UNIVERSITY OF STRATHCLYDE, Glasgow (GB) EP O 546593 A1 6, 1993 EP 1064937 1, 2001 EP 1607 O92 A1 12/2005 (*) Notice: Subject to any disclaimer, the term of this EP 2098 250 A1 9, 2009 patent is extended or adjusted under 35 JP HO5-194188 A 8, 1993 U.S.C. 154(b) by 0 days. JP 2001-515854. A 9, 2001 JP 2001-322927 A 11, 2001 JP 2003-503340 A 1, 2003 (21) Appl. No.: 131582,926 JP 2004-300148 A 10, 2004 JP 2005-508326 A 3, 2005 (22) PCT Filed: Mar. 4, 2011 JP 2005-508327 A 3, 2005 JP 2005-508328 A 3, 2005 (86). PCT No.: PCT/GB2O11AOOO3O7 JP 2005-510477 A 4/2005 JP 2008-517970 A 5, 2008 JP 2009-514989 4/2009 S371 (c)(1), WO WO99,12524 A1 3, 1999 (2), (4) Date: Oct. 2, 2012 WO WOO1 OO181 A2 1, 2001 WO WOO3,O266.15 A2 4/2003 (87) PCT Pub. No.: WO2011/107750 WO WOO3,O26625 A1 4/2003 WO WO 03/026626 A2 4/2003 PCT Pub.
    [Show full text]
  • Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
    Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä xx päivänä maaliskuuta 2016 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § Lääkeaineet ovat valmisteessa suolamuodossa Luettelon tarkoitus teknisen käsiteltävyyden vuoksi. Lääkeaine ja sen suolamuoto ovat biologisesti samanarvoisia. Tämä päätös sisältää luettelon Suomessa lääk- Liitteen 1 A aineet ovat lääkeaineanalogeja ja keellisessä käytössä olevista aineista ja rohdoksis- prohormoneja. Kaikki liitteen 1 A aineet rinnaste- ta. Lääkeluettelo laaditaan ottaen huomioon lää- taan aina vaikutuksen perusteella ainoastaan lää- kelain 3 ja 5 §:n säännökset. kemääräyksellä toimitettaviin lääkkeisiin. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ulkoisesti 2 § käytettynä parantaa, lievittää tai ehkäistä sairautta Lääkkeitä ovat tai sen oireita ihmisessä tai eläimessä. Lääkkeeksi 1) tämän päätöksen liitteessä 1 luetellut aineet, katsotaan myös sisäisesti tai ulkoisesti käytettävä niiden suolat ja esterit; aine tai aineiden yhdistelmä, jota voidaan käyttää 2) rikoslain 44 luvun 16 §:n 1 momentissa tar- ihmisen tai eläimen elintoimintojen palauttami- koitetuista dopingaineista annetussa valtioneuvos- seksi, korjaamiseksi tai muuttamiseksi farmako- ton asetuksessa kulloinkin luetellut dopingaineet; logisen, immunologisen tai metabolisen vaikutuk- ja sen avulla taikka terveydentilan
    [Show full text]